Skip to main content
All lobbying filings

CROSSROADS STRATEGIES, LLC

CROSSROADS STRATEGIES, LLC filed a Q2 report for EISAI, INC. on July 16, 2026, reporting $50,000 in lobbying income.

Lobbying for EISAI, INC. · human health care company

All filings by CROSSROADS STRATEGIES, LLC · Everything EISAI, INC. has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 16, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act (H.R.8800/S.4784); PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models); drug pricing.

Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Issues related to supply chain and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

 Bills named in this filing 4
  • H.R. 8800
    National Defense Authorization Act for Fiscal Year 2027
  • S. 4784
    National Defense Authorization Act for Fiscal Year 2027
  • S. 891
    Bipartisan Health Care Act
  • H.R. 1
    One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem